The National Institute for Health and Clinical Excellence (NICE) has rejected another cancer drug for the NHS due to its cost.
It means at least five cancer drugs have been declined by the agency for NHS use in the last year on cost related grounds. Fulvestrant, known commercially as Faslodex and manufactured by AstraZeneca, is designed to delay the growth of a particular type of advanced breast cancer. However, NICE said it did not represent a good use of NHS resources. As COVER previously reported, Avastin, which is also used to treat metastatic breast cancer, and three leukaemia drugs have been rejected this year. The importance of price for NHS drugs was further highlighted last week when the body r...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
